Navigation Links
Royalty Pharma Notes Elan Sales Process Offers Shareholders No Certainty
Date:6/14/2013

through the website maintained by the SEC at www.sec.gov or by directing a request to any of the persons listed above.

The Offer is and will be made in the United States pursuant to the US Exchange Act subject to certain exemptive relief which has been granted in respect of the Offer by the SEC and otherwise in accordance with the requirements of the Irish Takeover Rules. Accordingly, the Offer will be subject to disclosure and other procedural requirements, including with respect to withdrawal rights, offer timetable, settlement procedures and timing of payments that may be different from those typically applicable under U.S. domestic tender offer procedures and law. In addition, the Original Offer Document, the Revised Offer Document, the Further Revised Offer Document and any other documents relating to the Offer have been or will be prepared in accordance with the Irish Takeover Rules and Irish disclosure requirements, format and style, all of which may differ from those in the United States.

Elan is incorporated under the laws of Ireland. Some of the directors of Elan are resident in countries other than the United States. As a result, it may not be possible for United States holders of Elan Stock to effect service of process within the United States upon Elan or such directors of Elan or to enforce against any of them judgements of the United States predicated upon the civil liability provisions of the federal securities laws of the United States. It may not be possible to sue Elan or its officers or directors in a non-US court for violations of US securities laws. In addition, US holders of Elan Stock should be aware that, if Royalty Pharma elects to proceed pursuant to a scheme of arrangement (as described
'/>"/>

SOURCE Royalty Pharma
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Royalty Pharma Increases Offer to Acquire Elan to $13.00 Per Share in Cash Plus a Contingent Value Right of Up to $2.50 Per Share
2. Royalty Pharma Statement Regarding Elan Law Suits
3. Cadwalader Advises Elan Corporation in Billion Dollar Royalty Deal
4. Royalty Pharma Statement Regarding Elan Proposal
5. PDL BioPharma Provides Third Quarter 2012 Royalty Revenue Guidance of $85 Million
6. Cowen Healthcare Royalty Partners Raises $1 Billion
7. Smart Consulting Group and The Catalyst Group Form Alliance to Supply Quality Compliance Consulting Services For the Pharmaceutical Industry
8. Pursuit's Elissa Guerra and Eunjoo Pluenneke to Present on Mobile Strategy at Digital Pharma West Conference
9. MEI Pharma Adds Former YM BioSciences CEO Nick Glover To Board Of Directors
10. Frost & Sullivan Recognizes Sciformixs Continued Growth in the Increasingly Complex Pharmaceutical KPO Market
11. Auxilium Pharmaceuticals, Inc. To Present At The Goldman Sachs 34th Annual Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... Intarcia Therapeutics, Inc. today announced the presentation ... cost and predictability of non-adherence in type 2 diabetes ... the European Association for the Study of Diabetes (EASD). ... Ph.D., of Analysis Group, Inc. presented data from the ... to characterize the prevalence of non-adherence and serial non-adherence, ...
(Date:9/17/2014)... - SQI Diagnostics Inc. (TSX-V: SQD) (OTCQX: SQIDF), a ... and products for advanced microarray diagnostics, today announced that ... the United States on the ... September 17, 2014 on the OTCQX under the symbol ... TSX Venture Exchange under its existing symbol SQD. ...
(Date:9/17/2014)... California , 17 de septiembre de ... ("la compañía"), principal proveedor mundial de soluciones ... las ciencias de la vida, anunció hoy ... de logística global con sede en Rótterdam, ... base de clientes Europa en rápido crecimiento. ...
(Date:9/17/2014)... , September 17, 2014 ... of action from a truly novel class ... MGB Biopharma, a biopharmaceutical company developing ... today that it has secured £4.0m ($6.4m) ... antibacterial, MGB-BP-3, against a range of Gram-positive ...
Breaking Biology Technology:Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 2Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 3Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 4Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 5SQI Diagnostics to begin Trading on the OTCQX Marketplace in the United States 2SQI Diagnostics to begin Trading on the OTCQX Marketplace in the United States 3Cryoport contrata a Broekman Group para mejorar su apoyo operativo y logístico en Europa 2Cryoport contrata a Broekman Group para mejorar su apoyo operativo y logístico en Europa 3Cryoport contrata a Broekman Group para mejorar su apoyo operativo y logístico en Europa 4Cryoport contrata a Broekman Group para mejorar su apoyo operativo y logístico en Europa 5MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 2MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 3MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 4MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 5MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 6MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 7
... Inc., (TSX: IXS.V; OTC Bulletin Board: IXSBF),( http://www.ixsbio.com ... of monoclonal antibodies based on its Dynamic Cross ... a large scale,primate study of DXL625 (CD20), the ... study in cynomolgus monkeys of DXL625, an antibody,directed ...
... Odyssey Thera, Inc. announced,that it has received a ... progress a discovery stage drug candidate into,pre-clinical development. ... as part of the ongoing collaboration with Pfizer., ... of the collaboration with,Pfizer," said John K. Westwick, ...
... (OTC,Pink Sheets: AIMM) today reported a net loss of $86,000, ... ended June 30, 2008, compared with,a net loss of $62,000, ... months ended June 30, 2007. For the six months ended ... share basic and diluted, compared,with net loss of $54,000, or ...
Cached Biology Technology:InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625 2AutoImmune Inc. Reports 2008 Second Quarter Financial Results 2AutoImmune Inc. Reports 2008 Second Quarter Financial Results 3
(Date:9/17/2014)... affordable health care to reproductive technologies, the justice ... ability of people to identify key issues, articulate ... and find the most defensible ways forward. But ... these societal conversations?, The Hastings Center and the ... have teamed up to publish a series of ...
(Date:9/17/2014)... UT Arlington engineering professor and his doctoral student have ... can accumulate water collected from fog and dew., The ... world or deserts around the globe., Cheng Luo, professor ... Heng, PhD candidate in the same College of Engineering ... 25 edition of ACS, (American Chemical Society) ...
(Date:9/17/2014)... has developed, very cleverly, some lessons on how to ... said Joseph Shaw, director of the Optical Technology Center ... structures at the nanoscale, we,ll discover them." , Some ... August during a conference called "The Nature of Light: ... of the University of Arizona College of Optical Sciences. ...
Breaking Biology News(10 mins):Why bioethics literacy matters 2Why bioethics literacy matters 3Shorebird's beak inspires UT Arlington research on water collection 2Nature's designs inspire research into new light-based technologies 2Nature's designs inspire research into new light-based technologies 3
... may not be the answer to mitigating climate change by ... to an international team of plant biologists. The researchers found ... fungi (AMF) -- a type of fungus that is often ... then leads to higher decomposition rates of organic materials, said ...
... the methane on Earth comes from the ocean,s oxygen-rich waters, ... this potent greenhouse gas. Now researchers report that they have ... the most abundant microbes on the planet. The findings ... who made the discovery did not set out to explain ...
... part of the marine ecosystem, fostering biodiversity and protecting ... with pollution and harmful fishing practices, are one of ... One of the solutions to the crisis ... Tel Aviv University,s Department of Molecular Microbiology and Biotechnology, ...
Cached Biology News:Plants' fungi allies may not help store climate change's extra carbon 2Study identifies prime source of ocean methane 2Study identifies prime source of ocean methane 3Viruses could be the key to healthy corals 2
... a simple high performance method for removing ... without significant dilution of protein solution. ... Detergent-OUT Spin column and collect detergent free ... removing detergent from a maximum of 0.2 ...
... Chemicon Detergent-OUT SDS Kit is a simple ... protein solutions. Removes detergents without significant ... the protein solution on the Detergent-OUT Spin ... Med columns are suitable for removing ...
... from frozen embedded tissue blocks, which are ... ensure the highest quality. Tissues of each ... sectioned at a thickness of 7 microns ... large (3-5 mm in diameter) in comparison ...
... Zyagen tissue microarrays are derived from frozen ... rigorous quality control procedures to ensure the ... manually assembled in one block, sectioned at ... coated slides. Sections are large (3-5mm in ...
Biology Products: